FIT Biotech Oy: FIT Biotech Oy’s Extraordinary General Meeting held on January 26th 2017 appointed Eero Rautalahti to the Board of Directors. – FIT Biotech

Reports and Releases

FIT Biotech Oy: FIT Biotech Oy’s Extraordinary General Meeting held on January 26th 2017 appointed Eero Rautalahti to the Board of Directors.

FIT Biotech Oy

Company release January 26, 2017 at 22:00

FIT Biotech Oy's Extraordinary General Meeting held on January 26th 2017 appointed Eero Rautalahti to the Board of Directors.

FIT Biotech Oy's ("Company") Extraordinary General Meeting decided the number of board members to be as six. The Extraordinary General Meeting appointed LL.M. Solicitor Eero Rautalahti as a new board member as proposed by the Board of Directors. Eero Rautalahti has practiced law in London since 1995. He has advised on numerous IPOs (initial public offerings) on several different markets, including primary listings abroad and early-stage IPOs. Currently he is working as consultanting partner with McCarth Denning Ltd. in London.

Chairman of the board, Juha Vapaavuori: "Eero Rautalahti provides the Company's board with valuable competence and additional experience from the field of international business law. We warmly welcome Eero to reinforce the board of FIT Biotech Oy."

Juha Vapaavuori (chairman), Chitra Bharucha, Erkki Pekkarinen, Rabbe Slätis and Mart Ustav will continue to serve as board members.

The minutes of the extraordinary general meeting will be published on FIT Biotech's website on February 2, 2017, at the latest.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines. 

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech K shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media

Back to list